While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

The most negatively impacted sectors are frozen, refrigerated, general food and beverages. Circana found GLP-1 users’ monthly ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two ...